Zai Lab Limited (9688.HK)
Discovers and sells cancer and immunology drugs for patients in China and globally.
14.40-0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-50.2%
The outlook
Zai Lab (9688.HK) has strong analyst backing with a consensus rating leaning heavily toward buy, and the average price target sits about 46% above the current price. The stock is trading well below both its 50- and 200-day moving averages and sits near the lower end of its 52-week range. The overall sentiment is neutral, reflecting a disconnect between bullish analyst views and the stock's current technical position.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 10 analysts
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +46% vs current price
Analyst price target
~12-month · 10 analysts20.97average target+45.6% vs now
Now 14.40
Low 15.04High 28.01
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$16.26B
52-wk high
32.35
52-wk low
12.31
50-day avg
14.52
200-day avg
15.52
Trailing P/E
—